Merus NV at Citi BioPharma Conference Transcript
So second to last session of the day, I got [Yamaha Tarvitz] That's one of the biotech analysts here at Citi. It's my pleasure to have with me the CEO of Merus, Bill Lundberg. Bill, thank you for doing this. Appreciate it.
Yeah. Let's -- maybe we can just start with a high-level overview of the platform and what are the key programs. And then we can go program by program after that.
Well, first, thanks, Yigal. I appreciate the continued support from you and Citi and your entire team. Really appreciate all the support and help you've provided Merus recently and also over the years. Merus is a clinical-stage company with multiple clinical stage assets, several of which are already showing really encouraging data to date.
We are focused on bispecific antibodies in oncology, multi-specific antibodies in oncology. The age of the bispecific antibody is really here now. With around 10 approved products and multiple others nearing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |